AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04775745
Drug: LP-168
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the dose escalation phase, LP-168 will be given once or twice daily at the following dose levels:100 mg QD,150 mg QD, 100 mg BID, 300 mg QD, 150 mg BID, 450 mg QD, 225 mg BID, 600 mg QD, 800 mg QD, and 1000 mg QD.
Trial: NCT04775745
Drug: LP-168
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the dose expansion phase, subjects will receive once or twice daily dose of LP-168 at the Recommended Phase 2 Dose (RP2D). The RP2D may be as high as the MTD and will be determined following evaluation of Phase I Dose Escalation results.
Trial: NCT05472467
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1, 21 days for one cycle, up to 4 cycles.~Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles.
Trial: NCT05955105
Drug: ILB-2109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ILB-2109 tablets will be administered by mouth every day in 21-day cycles
Trial: NCT06284746
Drug: Tirolizumab+SOX/XELOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirolizumab combined with chemotherapy(SOX/XELOX) regimen. The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
Trial: NCT06284746
Drug: SOX/XELOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple chemotherapy regimen (SOX/XELOX regimen). The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
Trial: NCT04480086
Drug: Mivebresib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet: Oral
Trial: NCT05414981
Drug: ABI-H3733
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg or 100 mg tablets for oral administration
Trial: NCT05414981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg or 100 mg tablets for oral administration
Trial: NCT06353828
Drug: CBD, synthetic form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol enema
Trial: NCT06353828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo enema
Trial: NCT06287229
Drug: Hyper-CVAD
RxNorm normalized name: Hyper-Sal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV Participants younger than 60 years of age, you will receive hyper-CVAD.
Trial: NCT06287229
Drug: Mini-hyper-CVD
RxNorm normalized name: Hyper-Sal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV Participants 60 years of age or older, you will receive mini-hyper-CVD
Trial: NCT05330325
Drug: Norditropin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norditropin® will be administered s.c. once daily using FlexPro® pen-injector.
Trial: NCT06273891
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg IV every 6 hours for 48 hours, followed by 250 mg PO or 333 mg PO every 8 hours for 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days
Trial: NCT06273891
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 1 gm PO once or 500 mg PO followed by 250 mg PO daily for a total of 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days
Trial: NCT00002318
Drug: Doxorubicin hydrochloride (liposomal)
RxNorm normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002318
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04764214
Drug: 3rd generation EGFR-TKI
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osimertinib will be administered orally at the dose of 80 mg once daily.
Trial: NCT05428943
Drug: OPT101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-mer peptide derived from the sequence of mouse CD154.
Trial: NCT05663411
Drug: SHR6508
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR6508
Trial: NCT06461975
Drug: artificial tear (Sodium Hyaluronate 2 mg/ml) eye drops.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The second group had the first examination done using the Benoxinate HCL drops Benox ® eye drops and the second using the tear substitute Polyfresh ®given just before the ROP screening.
Trial: NCT05877430
Drug: CJRB-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Phase 1, one or two capsules of CJRB-101 will be given every day. In Phase 2, the CJRB-101 dose selected from Phase 1 will be given every day.
Trial: NCT05526443
Drug: all approved chemotherapeutic agents from second line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all approved chemotherapeutic agents from second line
Trial: NCT05357690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of saline injected in the plane of the right stellate ganglion
Trial: NCT06281470
Drug: WS016 Single Dose(12g)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WS016 12g, to be administered orally as a single dose.
Trial: NCT06281470
Drug: WS016 Single Dose(24g)
RxNorm normalized name: NEEDLE 24G 1IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WS016 24g, to be administered orally as a single dose.
Trial: NCT06281470
Drug: WS016 Single Dose(36g)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WS016 36g, to be administered orally as a single dose.
Trial: NCT06281470
Drug: WS016 Single Dose(48g)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WS016 48g, to be administered orally as a single dose.
Trial: NCT06281470
Drug: SAD matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, to be administered orally as a single dose.
Trial: NCT06281470
Drug: WS016 Multiple Dose(12g)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WS016 12g, to be administered orally once daily for a consecutive period of 7 days.
Trial: NCT06281470
Drug: WS016 Multiple Dose(24g)
RxNorm normalized name: NEEDLE 24G 1IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WS016 24g, to be administered orally once daily for a consecutive period of 7 days.
Trial: NCT06281470
Drug: WS016 Multiple Dose(48g)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WS016 48g, to be administered orally once daily for a consecutive period of 7 days.
Trial: NCT06281470
Drug: MAD matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, to be administered orally once daily for a consecutive period of 7 days.
Trial: NCT05421312
Drug: sampling blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the reimplantation, 3 serum samples will be taken at different timepoint during the procedure.
Trial: NCT05421312
Drug: Sampling bone tissue
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the reimplantation 2 cortical bone samples will be taken at different timepoints during the procedure.
Trial: NCT05082779
Drug: CS0159
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT04934072
Drug: FKS518
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneously by single-use prefilled syringe (PFS)
Trial: NCT04669600
Drug: SAR445088 (BIVV020)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution for injection
Trial: NCT04897321
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA. Intravenous
Trial: NCT05115903
Drug: Standard dose of TNFi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab)
Trial: NCT04660747
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants or vitamin K antagonists. Please note that the study is fully observational. The choice of anticoagulant type and duration of treatment are left at the discretion of the treating physicians and patients. No treatment, intervention, or examinations are imposed on patients in the context of this study.
Trial: NCT04805541
Drug: Mydriatic Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered mydriatic medication to dilate their pupils.
Trial: NCT06323525
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
Trial: NCT06224673
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ophthalmologic drops given topically to participants for an eye toxicity substudy
Trial: NCT05107856
Drug: PRT1419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT1419 will be administered by intravenous infusion
Trial: NCT04570501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) administered by continuous intravenous (IV) infusion
Trial: NCT05929716
Drug: Radiation
RxNorm normalized name: Miaderm Radiation Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT05472766
Drug: Direct Acting Oral Anticoagulant starting at Day 30
RxNorm normalized name: DIRECT BLUE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
Trial: NCT05472766
Drug: Direct Acting Oral Anticoagulant starting at Day 90
RxNorm normalized name: DIRECT BLUE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
Trial: NCT06210750
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06210750
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06210750
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06210750
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT05105464
Drug: SYHA1815
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive SYHA1815 orally.
Trial: NCT04804605
Drug: ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-151 Cream
Trial: NCT05076253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care
Trial: NCT06396078
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg PO BID x 7 days (in addition to ceftriaxone and metronidazole)
Trial: NCT06396078
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 1 g PO x 1 dose (in addition to ampicillin and amoxicillin)
Trial: NCT06396078
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg IV q 6 hours x 48 hours followed by erythromycin 333 mg PO TID for an additional 5 days (in addition to ampicillin and amoxicillin)
Trial: NCT04711980
Drug: Mudan granule
RxNorm normalized name: Sudan III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mudan granule,a traditional Chinese medicine formula,consists of nine Chinese herbs.~Other: Standard medical care.Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Trial: NCT04711980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granule(Placebo) is in accordance with Mudan granule in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Trial: NCT05662111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is given in capsules and are administered orally. During the study, participants will receive placebo in four periods of two weeks during the twelve months of follow-up.
Trial: NCT06496282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive placebo for improving sleep quality at lease 30 days in 6 weeks of study
Trial: NCT04784520
Drug: HA121-28 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA121-28 600 mg, po, QD×21 days, every 4 weeks (28 days)
Trial: NCT05079425
Drug: NXC736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT04071821
Drug: Zyrtec tablet 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cetirizine HCl 10mg tablet
Trial: NCT05079425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT04468542
Drug: Superior laryngeal nerve block - Placebo (saline)
RxNorm normalized name: ACS22Q55 NERVE BLOCK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-cc injection of saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
Trial: NCT04049591
Drug: Higher Dose UFH
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures
Trial: NCT04049591
Drug: Lower Dose UFH
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
Trial: NCT06014372
Drug: CAPEOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The neoadjuvant treatment regimen will consist of Oxaliplatin at a dose of 130mg/m2, administered intravenously over a period of more than 2 hours on Day 1, every 3 weeks; and Capecitabine at a dose of 1000mg/m2, orally, twice daily from Day 1 to Day 14, every 3 weeks, for a total of 4 cycles.
Trial: NCT04404387
Drug: Administration of vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).~The other name of the drug: Ascorbic acid.
Trial: NCT04404387
Drug: Administration of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo. Patients (in the control arm) will receive dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C. Placebo will be infused over 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute as per the infusion instructions of vitamin C.
Trial: NCT06224049
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy preconditioning will be performed before hNeo-T transfusion.
Trial: NCT02431221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04888819
Drug: DWP14012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
Trial: NCT04888819
Drug: DWP14012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
Trial: NCT04677959
Drug: Standard of Care Asthma Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma
Trial: NCT06360250
Drug: Tetanus human immunoglobulin (HTIG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus human immunoglobulin (HTIG)
Trial: NCT06360250
Drug: Whole-human anti-tetanus toxin monoclonal antibody A82 / B86 injection placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There were no active ingredients, and other ingredients were the same
Trial: NCT05171348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05646706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Trial: NCT05488340
Drug: LBP-EC01 0.1 x IV dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10\^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.
Trial: NCT05488340
Drug: LBP-EC01 0.01x IV Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10\^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.
Trial: NCT05488340
Drug: LBP-EC01 IV Infusion Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10\^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.
Trial: NCT05488340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose regimen selected from Part 1 of placebo (Tris buffer).
Trial: NCT05488340
Drug: LBP-EC01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose regimen selected from Part 1 of LBP-EC01 (1x10\^10 - 1x10\^13 PFU) per dose.
Trial: NCT05488340
Drug: TMP/SMX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
Trial: NCT06385730
Drug: neoadjuvant anti-PD-1
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor (toripalimab) 240mg, day 1，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators
Trial: NCT06293820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Trial: NCT05572723
Drug: Remifentanil 2 MG
RxNorm normalized name: remifentanil 2 MG
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil is an opioid; it has sedative, analgesic, and sympatholytic properties.
Trial: NCT05137184
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal Fentanyl
Trial: NCT05700097
Drug: Dengzhanxixin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental arms for low, and high dose for the standard protocol
Trial: NCT05700097
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo control arm for the standard protocol
Trial: NCT06078670
Drug: CVL218
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm1: Triple negative breast cancer CVL218 is administered orally Triplelizumab injection was administered intravenously (IV) 240mg on D1 Paclitaxel injection (Kealil) 125mg /m2, D1, D8 administration Every 21 days for a drug cycle; Arm2: Gastric cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Paclitaxel injection (Taxol) 175mg /m2, D1 administration Every 21 days for a drug cycle; Arm3: Intestinal cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Fuquinitinib capsule 5mg QD orally, D1-14 administration Every 21 days is a medication cycle.
Trial: NCT04808323
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m\^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.
Trial: NCT04808323
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)
Trial: NCT06354114
Drug: SYHX2011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion, 260 mg/m\^2
Trial: NCT05192356
Drug: CKD-828, D097, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO